Investment
Features
FeesSafety
Academy
More
Pluang+

Compare SYSCO Corporation (SYY) vs Twist Bioscience Corp (TWST) Price & Performance

SYSCO CorporationTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

SYSCO Corporation vs Twist Bioscience Corp — how do they compare? SYSCO Corporation trades at $78.11 (market cap $38.47B), while Twist Bioscience Corp trades at $160.84 (market cap $10.08B). The key difference: SYSCO Corporation is far larger — about 3.8× Twist Bioscience Corp's market cap, and SYSCO Corporation pays a 2.81% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold SYSCO Corporation for 77 Days and Twist Bioscience Corp for 27 Days on average.

SYYTWST
Market Cap
$38.47B$10.08B
Volume
4,808,4654,229,037
Sector
Consumer StaplesHealth
52-Week High
$91.16$205.00
52-Week Low
$69.30$25.45
Typical Hold Time
77 Days27 Days
Enterprise Value
$51.65B$10.01B
Dividend Yield
2.81%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

SYSCO Corporation

Sysco Corporation (SYY) trades at $76.79, down 0.85% with a bearish technical outlook. The company shows solid revenue growth to $81.37B in 2025 but faces margin compression with net income margin at 2.08%. Recent developments include a $500M AI efficiency program and a $1.5B senior notes offering. Analyst consensus remains positive with 60% buy ratings and an $85.75 price target, representing 11.7% upside potential.

SYY offers value with a P/S ratio of 0.44x and dividend yield support, but faces execution risks on margin improvement and debt management. The stock trades below analyst targets, providing potential upside if the company delivers on its AI efficiency goals and maintains market leadership in food distribution.

Twist Bioscience Corp

TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.

The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

SYY

No sentiment data available yet.

TWST
37% Buy63% Sell
Avg holding period · 27 Days

Top news

Latest headlines on both assets

About SYSCO Corporation

Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.

Read more on SYY →

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST →